CNBX Pharmaceuticals Inc.
CNBX
$0.0024
$0.000420.00%
OTC PK
| 02/28/2025 | 11/30/2024 | 08/31/2024 | 05/31/2024 | 02/29/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -100.00% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -100.00% | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -100.00% | -- | -- |
| SG&A Expenses | -51.57% | -75.29% | -24.84% | -50.30% | -43.79% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -73.82% | -85.92% | -79.92% | -68.48% | -1.16% |
| Operating Income | 68.65% | 78.59% | 67.49% | 12.02% | 17.44% |
| Income Before Tax | 78.56% | 80.73% | 89.44% | 15.58% | 87.60% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 78.56% | 80.73% | 89.44% | 15.58% | 87.60% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 78.56% | 80.73% | 89.44% | 15.58% | 87.60% |
| EBIT | 68.65% | 78.59% | 67.49% | 12.02% | 17.44% |
| EBITDA | 73.10% | 85.80% | 57.32% | -14.43% | 17.18% |
| EPS Basic | 79.05% | 82.81% | 92.31% | 74.85% | 99.21% |
| Normalized Basic EPS | 65.85% | 82.50% | 81.54% | 75.00% | 94.38% |
| EPS Diluted | 79.05% | 82.81% | 92.31% | 74.85% | 99.21% |
| Normalized Diluted EPS | 65.85% | 82.50% | 81.54% | 75.00% | 94.38% |
| Average Basic Shares Outstanding | 3.58% | 12.07% | 33.99% | 235.76% | 1,478.62% |
| Average Diluted Shares Outstanding | 3.58% | 12.07% | 33.99% | 235.76% | 1,478.62% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |